NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Targeted Investigation of Microbiome Elimination

Phase 1

Terminated

Conditions: Atopic Dermatitis

Interventions: Biological: S. hominis A 9 Product
Drug: Placebo

First Posted Date: 2022-01-04

Last Posted Date: 2024-11-12

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 21

Registration Number: NCT05177328

Locations: 🇺🇸
University of California, San Diego: Dermatology Clinical Trials Unit, La Jolla, California, United States

Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali

Phase 1

Completed

Conditions: Malaria,Falciparum

Interventions: Biological: Pfs230D1-EPA/Matrix-M Vaccine
Biological: Verorab Rabies Vaccine

First Posted Date: 2021-11-26

Last Posted Date: 2024-05-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 80

Registration Number: NCT05135273

Locations: 🇲🇱
Malaria Research Training Center, Bamako, Mali

Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)

Phase 1

Recruiting

Conditions: Zika Virus

Interventions: Biological: Placebo
Other: ZIKV-SJRP/2016-184 Strain

First Posted Date: 2021-11-17

Last Posted Date: 2023-10-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 56

Registration Number: NCT05123222

Locations: 🇺🇸
Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States

Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

Phase 1

Conditions: Chronic Granulomatous Disease
Inflammatory Gastrointestinal Disease
Inflammatory Lung Disease
Inflammatory Skin Disease

Interventions: Drug: XELJANZ (tofacitinib)

First Posted Date: 2021-11-03

Last Posted Date: 2024-10-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT05104723

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)

Phase 2

Active, not recruiting

Conditions: Vaccine
Cytomegalovirus Infections
HIV Infections

Interventions: Biological: CMV-MVA Triplex
Biological: Placebo

First Posted Date: 2021-10-29

Last Posted Date: 2025-01-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 90

Registration Number: NCT05099965

Locations: 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸
Washington University Therapeutics (WT) CRS, Saint Louis, Missouri, United States
🇺🇸
Chapel Hill CRS, Chapel Hill, North Carolina, United States

and more 9 locations

International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)

Active, not recruiting

Conditions: COVID-19

First Posted Date: 2021-10-27

Last Posted Date: 2024-05-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 5399

Registration Number: NCT05096091

Locations: 🇮🇩
National Institute of Health Research and Development (NIHRD), Ministry of Health, Republic of Jakarta - RSU Kabupaten Tangerang, Tangerang, Indonesia
🇱🇷
Partnership for Research in Vaccines and Infectious Diseases in Liberia (PREVAIL) - Duport Road Health Center, Monrovia, Liberia
🇲🇽
Hospital General Dr. Manuel Gea Gonzalez (HGMGG), Mexico City, Mexico

and more 8 locations

Blood-Stage Plasmodium Vivax Cell Bank

Phase 1

Completed

Conditions: Malaria

Interventions: Biological: HMPBS02-Pv

First Posted Date: 2021-10-27

Last Posted Date: 2023-07-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 2

Registration Number: NCT05095272

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency

Phase 1

Recruiting

Conditions: Crohn's Disease
Glycogen Metabolism
Inflammatory Bowel Disease (IBD)

Interventions: Drug: Empagliflozin

First Posted Date: 2021-10-15

Last Posted Date: 2024-11-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT05078879

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI

Phase 1

Withdrawn

Conditions: HIV Infections

Interventions: Drug: 3BNC117-LS
Drug: 10-1074-LS

First Posted Date: 2021-10-15

Last Posted Date: 2023-09-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT05079451

Locations: 🇺🇸
Alabama CRS, Birmingham, Alabama, United States

Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases

Recruiting

Conditions: COVID-19
Healthy Volunteer
Vaccination

First Posted Date: 2021-10-15

Last Posted Date: 2024-10-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1200

Registration Number: NCT05078905

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy